A recent study by Fred Hutch biochemist Christopher Lapointe, PhD, and his colleagues, uses innovative lab techniques to ...

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...

Scientists have discovered an unexpected role for a protein already linked to devastating neurological diseases. The study ...

Codexis inks agreement with an innovator pharma company to manufacture 50 grams siRNA using its ECO Synthesis platform: Redwood City, California Friday, March 6, 2026, 11:00 Hrs [ ...

Patient samples from Macquarie's Neurodegenerative Diseases Biobank have made a long journey to Wyoming in the US to be used in development of a ...

An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

Alnylam is broadening its position in the area of RNA interference (RNAi) gene-silencing therapies for cardiovascular diseases via a partnership with Tenaya Therapeutics, claiming rights to use the ...

Using a CRISPR-based biosensor platform, researchers have detected microRNA biomarkers of Alzheimer’s disease, with the ...

Hepatitis B virus (HBV) infection remains an urgent global health concern, affecting hundreds of millions of people and significantly heightening the risk of severe liver complications, including ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and ...

Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured ...